Cvs Share Discussion Threads

[j0sekl] 13/10/2019 20:59

You have mistaken CVS the US pharma chain with the CVSG pet business.

florenceorbis 5 Sep '19 - 08:27 - 564 of 569
0 1 0
WASHINGTON -- A federal judge on Wednesday approved a Justice Department settlement that allowed CVS Health Corp.'s nearly $70 billion acquisition of health insurer Aetna Inc.

[j0sekl] 07/10/2019 20:38

A decent quarter, execution just needs to stay real and simple. Especially this environment. The market will punish mistakes and bad news.

[adrian j boris] 07/10/2019 08:36

Peel Hunt Buy down from 1,050.00 to 950.00 Reiterates

[florenceorbis] 27/9/2019 07:25

Dividends

It is proposed to pay a dividend of 5.5p per share in December 2019, a 10.0% increase on the 5.0p per share paid in 2018. The financial performance of the business and its strong cash generation support an increase in dividends whilst enabling the Group to retain sufficient funds for further investment in the business.

Outlook

CVS operates in a sector with favourable market and consumer trends, with pet owners increasingly willing to spend money on their pets and medical enhancements increasing the range of services we can offer.

Despite continued uncertainty over Brexit with the potential for a "hard" Brexit increasingly likely, the Board is confident that CVS is well positioned to avoid significant adverse impacts from the UK's decision to exit the EU. Pharmaceutical manufacturers and wholesalers are increasing their stock levels in order to reduce the risk of supply shortages and following the acquisition of Vet Direct, CVS now controls more of its equipment and consumables supplies.

The pace of growth in the UK economy may be impacted by Brexit uncertainty, but the veterinary sector has proven to be resilient in past periods of economic downturn and the Board believes CVS is sufficiently resilient to withstand any potential future downturn.

The performance of the business was considerably improved in the second half of the financial year and the Board is confident that the Group is well placed to deliver further enhancement in shareholder value in the forthcoming financial year.

I would like to thank all of our colleagues for their contribution to the past financial year. Their professionalism, dedication and commitment to providing the highest levels of clinical care to our customers and their animals forms the heart of our business. I look forward to working with them to continue the successful growth of CVS in the future.

Richard Connell

Non-Executive Chairman

27 September 2019

[florenceorbis] 27/9/2019 07:24

-- Revenue up 24.2% to GBP406.5m
-- Like-for-like sales growth for the Group of +5.2% (5)
-- Healthy Pet Club members up 10.8% to 401,000
-- Adjusted EBITDA up 14.5% to GBP54.5m
-- Adjusted earnings per share increased 10.1% to 46.7 pence per share
-- Cash generated from operations up 11.6% to GBP52.1m

-- Profit before income tax down 17.0% to GBP11.7m due to amortisation costs in relation to acquisitions

-- Leverage reduced to 2.08x at 30 June 2019
-- Significant improvement in second half
-- Now operate 510 surgeries across the UK, the Netherlands and the Republic of Ireland

[florenceorbis] 27/9/2019 07:22

CVSG Peel Hunt Buy UPS TARGET FROM 950.00 to 1,050.00 Reiterates

[florenceorbis] 05/9/2019 08:29

SEPTEMBER/27/2019 FY 2019 Earnings Release

[florenceorbis] 05/9/2019 08:27

This article is being republished as part of our daily reproduction of WSJ.com articles that also appeared in the U.S. print edition of The Wall Street Journal (September 5, 2019).

WASHINGTON -- A federal judge on Wednesday approved a Justice Department settlement that allowed CVS Health Corp.'s nearly $70 billion acquisition of health insurer Aetna Inc., removing a cloud of uncertainty for the merged company.

U.S. District Judge Richard Leon had spent months questioning whether the settlement did enough to protect competition and consumers in health-care markets, raising the possibility that he might not approve it.

The judge, in a first for a court review of a government merger settlement, convened hearings to consider live witness testimony from the deal's critics who said the Justice Department's deal with the companies was inadequate.

Judge Leon on Wednesday said the critics' testimony ultimately was unpersuasive. He said the health-care markets at issue in the case "are not only very competitive today, but are likely to remain so post-merger."

The settlement "is well within the reaches of the public interest," the judge concluded.

The Justice Department approved the CVS-Aetna deal nearly a year ago, requiring CVS to sell off Aetna's Medicare prescription drug-plan business.

CVS completed the acquisition weeks later and has been moving forward with the Aetna business ever since. It sold Aetna's Medicare assets to WellCare Health Plans Inc., as the department required.

The merger combined the nation's third-largest health insurer with CVS's sprawling network of pharmacies and its pharmacy-benefit-management business. The companies argued that their combination could lower costs and improve health care for consumers.

"CVS Health and Aetna have been one company since November 2018, and today's action by the district court makes that 100 percent clear," a CVS spokesman said. "We remain focused on transforming the consumer health care experience in America."

An array of parties, including the American Medical Association and consumer groups, lodged objections to the merger, saying the deal would have anticompetitive effects throughout the health-care supply chain, giving CVS an outsize role.

Judge Leon said while the complaints warranted serious consideration, the evidence wasn't sufficient to reject the government's settlement with the companies. He rejected critics' arguments that the merger would harm markets for Medicare prescription drug plans. He also said CVS is unlikely to use its strong market position in the management of pharmacy benefits to disadvantage companies that compete with CVS's newly expanded health-insurance business.

The AMA expressed disappointment in the ruling. "Despite an unprecedented review that dragged many details of this merger into the light, today's decision ultimately fails patients, will likely raise prices, lower quality, reduce choice, and stifle innovation," AMA president Patrice A. Harris said.

Wednesday's ruling will likely come as a relief to the Justice Department, which has seen repeated difficulties in Judge Leon's courtroom. The judge, while questioning whether the DOJ did enough to address the CVS-Aetna merger, last year rejected the department's bid to block AT&T Inc. from acquiring entertainment company Time Warner.

Assistant Attorney General Makan Delrahim, the department's antitrust chief, said the settlement "provides a comprehensive remedy to the harms the Justice Department identified." Approval of the settlement "protects seniors and other vulnerable customers," he said.

Write to Brent Kendall at [e-mail]



(END) Dow Jones Newswires

September 05, 2019 02:47 ET (06:47 GMT)

[maywillow] 01/8/2019 11:37

Peel Hunt Buy 950.00 - Reiterates

[maywillow] 28/7/2019 11:35

lomax99
28 Jul '19 - 11:15 - 561 of 561
0 0 0
They were ahead of the curve then.... Happy with stocks which do not get too much analyst coverage.

LOL

i tend to disagree regarding less analyst coverage

I reckon fewer analysts lead to manipulation, distorted views and if the share is really illiquide controlled share price and wider spreads

the more analysts to wider the market especially when one talks about maim stocks

THIS ONES BEEN A GEM THUS FAR MAY IT LONG CONTINUE

[lomax99] 28/7/2019 11:15

They were ahead of the curve then.... Happy with stocks which do not get too much analyst coverage.

[maywillow] 28/7/2019 10:46

Berenberg almost doubled its price target on the firm from 550p to 1,000p.

[ariane] 28/7/2019 09:11

COULD DO WITH MORE ANALYSTS TO COVER THIS COMPANY

THE COMING ERRK SHOULD BOTH INTERESTING AND EXCITING

CHEERS

[ariane] 28/7/2019 09:10

Josh White
Sharecast News
28 Jun, 2019 15:52
CVS Group raises earnings expectations after decent second half


Integrated veterinary services provider CVS Group updated the market on its trading on Friday, reporting that it achieved like-for-like sales growth of around 5.4% during the 11 month period in the year-to-date, and approximately 4.4% in its core practices division.


The AIM-traded firm, which was looking to the end of its financial year on 30 June, said it was expecting to report revenue for the full year in line with current consensus market expectations.

It said that in its interim results release, CVS noted that a number of actions were being taken by management to improve performance.

On Friday, it reported that as a result of those actions, the “encouraging progress” noted in the second half had continued.

As a result, the group now expected adjusted EBITDA performance for the full-year to be “comfortably above” current consensus market expectations.

“The Group will provide further details on its financial results for the year ending 30 June when it releases a pre-closed period statement on 26 July,” the CVS board said in its statement.

“The update will contain further insight into performance across the group's business and its continuing growth strategy.”

[ariane] 28/7/2019 09:07

Broker Forecast - Peel Hunt issues a broker note on CVS Group PLC
By BFN News | 10:30 AM | Friday 28 June, 2019

Factsheet CVS Group PLC Ord 0.2P (CVSG)


Peel Hunt today reaffirms its buy investment rating on CVS Group PLC (LON:CVSG) and raised its price target to 775p (from 700p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk


NOT VERY INSPIRING as current share price 948 GBp +7.30%

$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$


EDIT

I DO BELIEVE THE ABOVE TARGET WAS OUT OF DATE


CVSG Peel Hunt BUY ups from 775.00 to 950.00 Reiterates

[ariane] 28/7/2019 08:36

I never got round to buying CVSG, I WISH I HAD. Whow 12 years passed already

Looking at it afresh, i feel that it is more than fairly valued and i believe it will find it hard to break the 1000p resistence

i feel too that the share price will start to fall back if it cannot break resistence


Having said that others might well disagree and i wish you all continued success





Moving Averages analysis

Price and moving averages has closed above its Short term moving average.

Short term moving average is currently above mid-term; AND above long term moving averages.

From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and BULLISH in mid-long term.

Bollinger Bands Analysis

CVSG.L has closed above the upper band by 10.3%.

If the price is in a uptrend; then this upward trend has a good chance to continue. above the upper band by 10.3%.

If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 101.8% wider than normal.

The large width of the bands suggest high volatility as compared to CVSG.L's normal range.

The bands have been in this wide range for 2 bars. This is a sign that the current trend might continue.



Targets Six months: 1112.52 One year: 1299.42

Supports Support1: 740.84 Support2: 610.00

Resistances Resistance1: 952.50 Resistance2: 1112.52

[ariane] 28/7/2019 08:25

Summary

The company has solid fundamentals for a short-term investment strategy.

Strengths

There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar.

Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.

Over the past year, analysts have regularly revised upwards their sales forecast for the company.

For the past twelve months, EPS forecast has been revised upwards.

Analysts covering this company mostly recommend stock overweighting or purchase.

Weaknesses

Stock prices approach a strong long-term resistance in weekly data at GBp 1020.

The company sustains low margins.

With an expected P/E ratio at 60.77 and 42.51 respectively for both the current and next fiscal years, the company operates with high earnings multiples.

The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.

For the past year, analysts have significantly revised downwards their profit estimates.

The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.

[p winky] 27/7/2019 20:21

A most positive statement, could this surpass previous highs, especially if Aussie kiwi and South African vets can apply to work in the UK again under the s.o.l.

[bramble13] 22/7/2019 13:23

Which endorses my prediction that the share price could easily Reach 900p.

[j0sekl] 08/7/2019 01:17

Any example?

[bramble13] 07/7/2019 14:19

JOSEKI..I find the research very rewarding and don't have a problem finding a Winner, getting in is easy .....now ....getting out is a different kettle of fish. I think I may be a bit GREEDY.I can't active the full potential of my investment.

[j0sekl] 05/7/2019 16:18

Well said. P/E is important, just wanted to mention it's also positive to think about continual financial health and cashflow conversion into equity return.